The funds will be used to commercialise its cardiology technology and commence the first-in-human clinical study of Ceryx’s cardiac rhythm management device, Cysoni, later this year.
Cysoni, meaning synchronisation in Welsh, has been created specifically to help patients with heart failure. Cysoni continuously monitors the patient’s cardiorespiratory system, processing this information and generating precisely timed impulses which optimise the beating of the heart. Cysoni has the potential to restore cardiac performance; thus impacting heart failure symptoms; boost physical performance, relieve stress on the heart and even reverse cardiac remodelling indicative of heart failure, all of which goes towards improving the patient’s quality of life.
Using revolutionary biomimetic design principles and patented electronics, Ceryx created a range of smart bioelectronic devices that speak the same language as the human body. When integrated seamlessly into the body’s homeostatic systems, these special medical devices are able to interpret physiologic signals and generate a natural response in real-time, simulating the body’s natural functions. This treatment can be used to restore normal function in heart failure, as well as other conditions including hypertension, spinal cord injuries and endocrine disorders such as diabetes. With five years of rigorous laboratory testing and pre-clinical evaluations already under its belt, Ceryx’s technology has the potential to treat some of the world’s deadliest diseases.
Dr Stuart Plant, CEO of Ceryx said: “Our studies have found that Cysoni’s way of pacing the heart increased cardiac output by 20%, when compared with monotonic pacing. The benefits of this for cardiology patients are potentially life-changing and life-extending, because as well as enabling the heart to work more efficiently, Cysoni also repairs the structure of single heart cells. It’s a huge scientific breakthrough.”
Dr Plant added: “All the signs point to Cysoni being capable of not only making daily life better for those with heart problems, but also of improving the prognosis for even the most seriously ill cardiology patients. This latest round of funding will enable us to develop our technology for human use and embark on the next phrase of rigorous testing.”
Of the 26 million heart failure patients worldwide, around 50% die within five years of diagnosis. It’s a statistic Dr Plant and his team aim to change, with global use of Cysoni their target over the next five to ten years.
The Ceryx team, alongside scientists from the Universities of Auckland, Bath and Bristol, aims to begin in-human trials in the UK and New Zealand in the final quarter of 2022.
Dr Plant explained: “Cysoni will eventually be an implantable device, but for the purpose of the in-human trials we’ll use an external pacemaker device, loaded with Cysoni technology, to pace the hearts of patients with heart failure who have undergone a coronary artery bypass. Normally these patients receive pacing for a few hours after surgery and pacing is then removed. We will pace post-surgery for the whole time they remain in hospital, so we’ll build a really good picture of what Cysoni can do. If patients respond in the same way as our preclinical models, we should see significant improvements in their cardiac performance, which we’re confident will translate to improved outcomes.”